ReviewJournal of mammary gland biology and neoplasia2011
When tumor suppressor TGFβ meets the HER2 (ERBB2) oncogene.
Review in Journal of mammary gland biology and neoplasia, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 54 citations in OpenAlex.
- Bioinformatic Approach to Identify Positive PrognosticInternational journal of molecular sciences · 2025Article
- ERBIN limits epithelial cell plasticity via suppression of TGF-β signaling.FEBS letters · 2025Article
- Whole genome sequencing of HER2-positive metastatic extramammary Paget's disease: a case report.Orphanet journal of rare diseases · 2024Article
- HER2 phosphorylation induced by TGF-β promotes mammary morphogenesis and breast cancer progression.The Journal of cell biology · 2024Article
- An Insight into Molecular Targets of Breast Cancer Brain Metastasis.International journal of molecular sciences · 2022Review
- Significance of tumor heterogeneity of p-Smad2 and c-Met in HER2-positive gastric carcinoma with lymph node metastasis.BMC cancer · 2022Article
- Review
- Therapeutic Targeting of Nemo-like Kinase in Primary and Acquired Endocrine-resistant Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Article
- Global Protease Activity Profiling Identifies HER2-Driven Proteolysis in Breast Cancer.ACS chemical biology · 2021Article
- TGFβ and EGF signaling orchestrates the AP-1- and p63 transcriptional regulation of breast cancer invasiveness.Oncogene · 2020Article
- The functional switch of TGF-β signaling in breast cancer.Oncotarget · 2019Article
- Transforming growth factor beta 1 (TGFβ1) polymorphisms and haplotype structures have dual roles in breast cancer pathogenesis.Journal of cancer research and clinical oncology · 2018Article
- Identification and characterization of biomarkers and their functions for Lapatinib-resistant breast cancer.Medical oncology (Northwood, London, England) · 2017Article
- HER2 in Breast Cancer Stemness: A Negative Feedback Loop towards Trastuzumab Resistance.Cancers · 2017Review
- Ascending the PEAK1 toward targeting TGFβ during cancer progression: Recent advances and future perspectives.Cancer cell & microenvironment · 2016Article
- EGFR and HER2 signaling in breast cancer brain metastasis.Frontiers in bioscience (Elite edition) · 2016Article
- Pathogenesis of Breast Cancer Metastasis to Brain: a Comprehensive Approach to the Signaling Network.Molecular neurobiology · 2016Review
- Attenuated transforming growth factor beta signaling promotes metastasis in a model of HER2 mammary carcinogenesis.Breast cancer research : BCR · 2014Article
- Cutting the brakes and flooring the gas: how TMEPAI turns TGF-β into a tumor promoter.Genes & cancer · 2014Article
- Inhibition of Integrin-HER2 signaling by Cucurbitacin B leads to in vitro and in vivo breast tumor growth suppression.Oncotarget · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
Despite its tumor suppressive role in normal mammary epithelial cells, TGFβ has been reported to promote the migration, invasion and survival in breast cancer cells overexpressing the HER2 (ERBB2; neu) oncogene, and to accelerate the metastasis of neu-induced mammary tumors in mice. A clearer understanding of the molecular mechanisms underlying the crosstalk between TGFβ and HER2 has started to emerge. In recent studies reviewed here, the synergistic effect of TGFβ and HER2 on tumor progression has been shown to likely be a combined result of two distinct features: (1) loss of TGFβ's tumor suppressive effect through functional alterations in the anti-mitogenic effect of Smad-mediated transcription, and (2) gain of pro-survival and pro-migratory function through HER2-dependent mechanisms. In HER2-overexpressing breast cancer, this crosstalk results in increased cancer cell proliferation, survival and invasion, accelerated metastasis in animal models, and resistance to chemotherapy and HER2-targeted therapy. Thus, the transformed cellular context imparted by constitutively active HER2 signaling, as a consequence of HER2 gene amplification or overexpression, aborts the tumor suppressive role of TGFβ and facilitated the oncogenic role of this pathway. In turn, TGFβ potentiates oncogenic HER2 signaling by inducing shedding of the ERBB ligands and clustering of HER2 with integrins. Here we discuss recent studies examining Smad-dependent and -independent mechanisms of crosstalk between TGFβ and HER2. Therefore, blockade of TGFβ:HER2 crosstalk may suppress breast cancer progression and metastasis, and enhance the efficiency of conventional therapies in patients with HER2-overexpressing breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.